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Introduction
Uterine fibroids (leiomyoma or myoma) are the most
common gynecologic tumors in women of reproductive
age. The prevalence of leiomyoma reportedly ranges
from 20% to 50% of women over the age of 30 years
[1]. However, very little is known about its molecular
pathogenesis. Similarly, the regulation of its growth 
is poorly understood. It is believed that angiogenesis,
the process by which new capillaries develop from pre-
existing blood vessels, may be involved. In fact, leiomy-
oma is related to complex autocrine and paracrine
interactions, and the effects of sex-steroid hormones
on uterine cells [2]. Genesis and growth-promoting
factors are responsible for their development.
Growth factors are multifunctional cytokines that
regulate many biological functions, ranging from growth
and differentiation to cellular apoptosis [3]. Growth fac-
tors are also associated with cellular proliferation and
differentiation, angiogenesis, extracellular matrix modi-
fication and immunomodulation [3]. Hyperexpressed
growth factors and increased production of growth
factor peptides may elicit autocrine effects or act as
cocarcinogens [4]. Growth factors function as autocrine
or paracrine mediators of estrogen to maintain, differ-
entiate and enhance tumor growth [2].
Growth factors are involved in the pathogenesis of
leiomyomas and regulation of angiogenesis, which is nec-
essary for the growth of leiomyomas [5]. Growth factors
could preferentially promote the growth of leiomyoma
cells compared with myometrial cells [6]. Thus, growth
factors and their receptors may play important roles 
in the pathogenesis of leiomyomas [7]. The presence
of growth hormone receptor mRNA suggests that the
human uterus is a target tissue for growth hormone
action [8]. Uterine leiomyosarcomata has been shown
to oversecrete growth hormone [7].
LEIOMYOMA AND VASCULAR ENDOTHELIAL
GROWTH FACTOR GENE POLYMORPHISMS: 
A SYSTEMATIC REVIEW
Chi-Chen Chang1,3, Yao-Yuan Hsieh2,3, Wen-Hsin Lin4, Chih-Sheng Lin1*
1Department of Biological Science and Technology, National Chiao Tung University, 2School of Chinese Medicine, 
College of Chinese Medicine, 4School of Pharmacy Undergraduate Program, Department of Medicine, 
China Medical University, 3Division of Infertility Clinic, Hsieh Yao-Yuan Womens’ Hospital, Taichung, Taiwan.
SUMMARY
Leiomyomas (myoma or fibroid) are the most common gynecologic tumors that occur in women of reproduc-
tive age, but their molecular pathogenesis is still unknown. Since the growth of leiomyomas involve numerous
vascular factors, an association between the leiomyoma and growth factors is suspected. Vascular endothelial
growth factor (VEGF) is one of the most important angiogenic growth factors. VEGF regulates angiogenesis and
mediates sex steroid-induced cell growth and differentiation. VEGF-mediated activities seem to contribute to
the pathogenesis of leiomyoma. Genetic variations, including polymorphisms, in VEGF might also be associated
with the complex pathogenesis of leiomyomas. Here, we performed a systematic review of the roles of VEGF and
its polymorphisms in the pathogenesis of leiomyoma. [Taiwan J Obstet Gynecol 2010;49(3):247–253]
Key Words: leiomyoma, polymorphism, vascular endothelial growth factor
*Correspondence to: Dr Chih-Sheng Lin, Department
of Biological Science and Technology, National
Chiao Tung University, 75 Po-Ai Street, Hsinchu
300, Taiwan.
E-mail: lincs@mail.nctu.edu.tw
Accepted: January 26, 2010
The mRNA expression of growth factors is regulated
by ovarian hormones [9]. Estrogen may exert its mito-
genic effects on leiomyomas via estrogen-dependent
growth factors [10]. Hypoestrogenism caused by a
gonadotrophin-releasing hormone analog is also asso-
ciated with decreased levels of growth factors [11].
Growth factors are also responsible for uterine myoge-
nesis [10]. Changes in growth factor binding to the
myometrium may play a role in the pathogenesis of
leiomyomata [12].
Among the growth factor family, vascular endothe-
lial growth factor (VEGF) might be one of the most
important angiogenic growth factors in terms of angio-
genesis regulation [13]. VEGF is a potent proangiogenic
factor, and is an essential growth factor for vascular
endothelial cells. The development of leiomyoma is
associated with exposure to ovarian sex steroids and
an increased requirement for vascular supply for their
growth. These observations suggest that VEGF and
other proangiogenic factors might be involved in the
development of leiomyomas [14].
VEGF Expression
The contribution of VEGF to tumor angiogenesis is well
understood. VEGF is up-regulated in many tumors [15]
and VEGF protein was detected in the culture media
from a range of tumor cell lines [16]. VEGF mRNA was
also detected in numerous tumors and metastases,
with immunoreactivity for VEGF localized on tumor
cells and in the stromal matrix. VEGF might be released
into the surrounding stromal matrix, which might con-
tribute to tumor growth and metastasis in a paracrine
manner through angiogenesis and increased vascular
permeability. Some investigators have reported no cor-
relation between serum VEGF levels and tumor vascu-
lar density. These findings suggested VEGF may promote
tumor growth by direct pro-survival effects in tumor
cells [17].
VEGF and VEGF receptors (VEGFR) are expressed
by numerous endothelial and non-endothelial tumor
cells. VEGF exerts its biological effects by binding to
one of two tyrosine kinase receptors (VEGFR-1 and
VEGFR-2) [13]. VEGF plays a major role in leukemia
and lymphoma [18]. Furthermore, VEGF is highly ex-
pressed in a variety of solid tumors [19]. VEGF expres-
sion is also correlated with malignant disease progression
[20]. VEGF overexpression in tumors is associated with
increased angiogenesis, proliferation, and metastasis
[21]. Phosphorylated VEGFR was also observed in
numerous solid tumors, including lung cancers, breast
cancers, lymphoma, and melanoma [22]. Other than
endothelial cells, many peripheral cell types have stained
positive for phosphorylated VEGFR, including macro-
phages, fibroblasts, and myofibrils.
VEGF expression is potentiated by a variety of hor-
mones and cytokines. VEGF mediates angiogenesis in
a variety of estrogen target tissues [23]. VEGF expres-
sion was significantly correlated with estrogen recep-
tor status and inversely correlated with tumor grade
[24]. Meanwhile, estrogens increase the expression of
VEGF mRNA in the uterus [14]. VEGF is a stimulator
and prognostic factor for breast and uterine tumors
[14]. VEGF is regulated by estradiol and tamoxifen in
the uterus and by estradiol in breast cancer cells [14].
Furthermore, nitric oxide was reported to mediate VEGF
signaling [25]. The mitogenic effects of VEGF are inhib-
ited by antagonists of nitric oxide synthase [25]. VEGF
expression is also affected by p53 status [26].
VEGF and its receptors have been identified in sev-
eral reproductive tissues, including the endometrium
[27], placenta [28], fallopian tube, ovary [29], corpus
luteum, ovarian follicles, endometrial vessels, embry-
onic implantation sites [30], trophoblast cells, and
yolk sac [31]. VEGF contributes to luteal angiogenesis,
corpus luteum development, and progesterone pro-
duction during mid-pregnancy [32]. VEGF can diffuse
into the extracellular environment and might be pres-
ent in biological fluids, including peritoneal fluid and
blood [13].
VEGF expression is significantly higher in deeply
infiltrating endometriosis as well as during vasculariza-
tion [33]. VEGF exists in several isoforms, all of which
are potent stimulators of angiogenesis [34]. The dif-
ferential expression of VEGF in leiomyomas compared
with the adjacent myometrium indicates that local an-
giogenesis may be important in the development and
growth of leiomyoma [35]. High levels of VEGF in serum
and peritoneal fluid has been reported to be associ-
ated with increased mitotic activity in endometriotic
lesions [13].
VEGF gene expression
The VEGF gene is an important determinant of VEGF
plasma levels [36]. Endothelial cell proliferation, tubule
formation, and tumor growth may be diminished by
down-regulation of endogenous VEGF [37]. VEGF is
subject to multilevel regulation at the transcriptional,
posttranscriptional, translational, and posttranslational
levels during embryogenesis and in adulthood [38].
VEGF is produced by various cells, including vascular
smooth muscle, endothelial and inflammatory cells, and
has direct effects on vascular endothelial and smooth
muscle cells through the activity of receptor tyrosine
kinases [39]. VEGF has been shown to increase the
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ability of endothelial cells to produce nitric oxide, which
may improve endothelial function [40].
VEGF gene expression is modulated by a variety of
effectors, including cytokines [41,42], lipopolysaccharide
[43], hormones [41], and hypoxia [42]. Dysregulated
VEGF expression is implicated in the pathogenesis of a
number of diseases. Increased VEGF expression resulting
in inappropriate VEGF-induced angiogenesis is associ-
ated with tumor growth and metastasis [44], rheuma-
toid arthritis [45], and diabetic retinopathy [46]. The
ability to produce VEGF in response to hypoxia is asso-
ciated with the development of collateral vessels and
protection against myocardial disease [47].
The identification of the related genes is essential for
genetic diagnosis and gene therapy for genetic diseases.
Genetic studies of multifactorial diseases such as lei-
omyoma are difficult to perform because of uncertain-
ties of a polygenic trait. Biallelic expression of the gene
might lead to overexpression of growth factors and
increased mitogenic activity [7]. In our previous reports,
we found no associations between leiomyoma and poly-
morphisms in estrogen and androgen receptors, or in
interleukin (IL)-1 (IL-1β-511 promoter, IL-1β exon 5),
IL-4, tumor necrosis factor, p53 or p21 [48–52]. We
have also noted that the insulin-like growth factor II ApaI
polymorphism is associated with leiomyoma suscepti-
bility (Hsieh et al, unpublished data).
Regulation of the human VEGF gene, which is located
at chromosome 6p12-21, is extremely complex [52].
VEGF is a determinant of the rate and extent of angio-
genesis, playing a major role in endothelial mitogenesis.
Upregulation of VEGF may be related to metastases in
cancer, and may also play a role in cardiovascular patho-
physiology by initiating and propagating angiogenesis,
and the development of collateral vessels [42]. VEGF 
is a potent stimulus of vascular permeability that plays
a major role in embryonic vasculogenesis and adult
vascular remodeling [41]. VEGF is also required for
cyclic blood vessel proliferation in the female repro-
ductive tract [41]. VEGF induces endothelial cell prolif-
eration, promotes cell migration, and inhibits apoptosis.
Dysregulation of VEGF expression contributes to the
development of solid tumors by promoting tumor
angiogenesis [42].
Systematic Review
Numerous gene polymorphisms have been reported 
to be associated with the pathogenesis of leiomyoma,
including cytochrome P450c17a gene*A2 allele [53],
estrogen receptor*12 or 13 thymine-adenine dinucle-
otide repeat [54], insulin-like growth factor II gene and 
the small nuclear ribonucleoprotein polypeptide N gene [55].
However, some researchers found no association be-
tween VEGF genetic presentation and leiomyoma. Fur-
thermore, there was a non-significant difference between
VEGF mRNA levels in the proliferative and secretory
phases of the cycle [56].
Reviewing the MEDLINE database, we found some
reports describing associations between VEGF poly-
morphisms and individual disorders (Table). However,
few researchers have reported associations between
VEGF gene polymorphisms and leiomyoma. We recently
reported that the 5-UTR–460 polymorphism in the VEGF
gene might contribute to the pathogenesis of leiomy-
oma [57]. We also observed that VEGF T homozygotes
and T allele are associated with higher susceptibility of
leiomyoma development. These findings strongly sug-
gest a molecular correlation between VEGF and leiomy-
oma, and that VEGF is involved in the pathogenesis of
leiomyoma.
Genomic imprinting is defined as a gamete-specific
modification that causes differential expression of the
two alleles of a gene in somatic cells [58]. Alternation
or loss of imprinting (LOI) of growth factors is related
to oncogenesis, either through inactivation of a tumor
suppressor gene or activation of a growth-promoting
gene [59]. Biallelic expression of VEGF may be an early
event in tumorigenesis. When both alleles of the growth
factor are expressed in the tumor tissue, it is likely 
that more growth factor mRNA and protein will be
produced [60]. LOI may contribute to the growth of
these tumors through an autocrine or paracrine mech-
anism. With LOI, the growth factor is overexpressed,
contributing to the growth or development of the 
neoplasm [60].
Summary
In summary, we suggest that growth factors are asso-
ciated with the pathogenesis of leiomyomas. Poly-
morphisms in growth factor genes might play a role in
the complex pathogenesis of leiomyoma. If so, poly-
morphisms in the VEGF gene may be a useful marker
to predict susceptibility to leiomyoma. However, the
actual role of VEGF polymorphisms in the develop-
ment of leiomyoma warrants further studies. The long-
term aim was to find and develop useful markers for
early detection of these diseases. Our understanding of
the underlying biophysical and biochemical mechanisms
will help us to develop new diagnostic criteria beyond
histologic evaluation, and permit the identification
and validation of molecular targets for future drug 
discovery.
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